Symbols / QTTB $6.30 -7.62%
QTTB Chart
About
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 81.01M |
| Enterprise Value | 59.21M | Income | 29.82M | Sales | 53.74M |
| Book/sh | 3.27 | Cash/sh | 3.30 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -1.18 | PEG | — |
| P/S | 1.51 | P/B | 1.93 | P/C | — |
| EV/EBITDA | 3.42 | EV/Sales | 1.10 | Quick Ratio | 4.31 |
| Current Ratio | 4.85 | Debt/Eq | 36.52 | LT Debt/Eq | — |
| EPS (ttm) | -3.40 | EPS next Y | -5.36 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-10 06:00 | ROA | 13.71% |
| ROE | 125.06% | ROIC | — | Gross Margin | 64.35% |
| Oper. Margin | 85.38% | Profit Margin | 55.49% | Shs Outstand | 12.86M |
| Shs Float | 6.30M | Short Float | 8.84% | Short Ratio | 2.25 |
| Short Interest | — | 52W High | 7.80 | 52W Low | 1.34 |
| Beta | — | Avg Volume | 187.57K | Volume | 336.45K |
| Target Price | $14.33 | Recom | Buy | Prev Close | $6.82 |
| Price | $6.30 | Change | -7.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.33
Mean price target
2. Current target
$6.30
Latest analyst target
3. DCF / Fair value
$6.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.30
Low
$10.00
High
$20.00
Mean
$14.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | init | HC Wainwright & Co. | — → Buy | $13 |
| 2025-03-12 | main | Wells Fargo | Equal-Weight → Equal-Weight | $15 |
| 2025-02-11 | down | BMO Capital | Outperform → Market Perform | $3 |
| 2025-02-11 | down | Piper Sandler | Overweight → Neutral | $4 |
| 2024-12-12 | main | BMO Capital | Outperform → Outperform | $22 |
| 2024-12-12 | down | Guggenheim | Buy → Neutral | — |
| 2024-12-11 | main | Oppenheimer | Outperform → Outperform | $20 |
| 2024-12-11 | main | Piper Sandler | Overweight → Overweight | $20 |
| 2024-12-11 | down | Wells Fargo | Overweight → Equal-Weight | $16 |
| 2024-12-11 | down | Leerink Partners | Outperform → Market Perform | $9 |
| 2024-12-11 | down | Raymond James | Strong Buy → Outperform | $22 |
| 2024-12-06 | init | BMO Capital | — → Outperform | $64 |
| 2024-10-24 | init | Raymond James | — → Strong Buy | $90 |
| 2024-09-11 | init | Wells Fargo | — → Overweight | $95 |
| 2024-06-17 | init | Guggenheim | — → Buy | $100 |
| 2024-05-21 | init | Leerink Partners | — → Outperform | $54 |
| 2024-04-11 | init | Oppenheimer | — → Outperform | $50 |
| 2024-04-02 | init | Piper Sandler | — → Overweight | $45 |
- Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? - Yahoo Finance Fri, 13 Mar 2026 13
- $QTTB stock is up 17% today. Here's what we see in our data. - Quiver Quantitative ue, 10 Mar 2026 19
- Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire ue, 10 Mar 2026 10
- Wall Street experts predict Q32 Bio (QTTB) could surge by 103.55%: Is such a significant rise truly possible for this stock? - Bitget Fri, 13 Mar 2026 15
- Q32 Bio (QTTB) One Off Driven Q4 Profit Challenges Earnings Decline Narrative - simplywall.st hu, 12 Mar 2026 23
- Q32 Bio (NASDAQ:QTTB) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat Sat, 14 Mar 2026 11
- Best Momentum Stocks to Buy for March 13th - The Globe and Mail Fri, 13 Mar 2026 15
- Q32 Bio: Q4 Earnings Snapshot - KTVB ue, 10 Mar 2026 11
- Q32 Bio Stock (QTTB) Opinions on ADX-097 Asset Sale | QTTB Stock News - Quiver Quantitative Mon, 01 Dec 2025 08
- Q32 Bio Announces $10.5 Million Registered Direct Offering - PR Newswire ue, 17 Feb 2026 08
- $QTTB stock is up 19% today. Here's what we see in our data. - Quiver Quantitative Wed, 08 Oct 2025 07
- QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget ue, 02 Dec 2025 08
- Q32 Bio Breaks Out — But Can It Hold the Momentum? - Bitget Wed, 11 Mar 2026 04
- FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat hu, 12 Mar 2026 11
- H.C. Wainwright Maintains Buy on QTTB Q32 Bio Inc. March 2026 - Meyka ue, 10 Mar 2026 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2815 | 12708.0 | — | Sale at price 4.51 per share. | VIOLETTE SHELIA M | Officer | — | 2026-02-25 00:00:00 | D |
| 1 | 3995 | 18035.0 | — | Sale at price 4.51 per share. | KALOWSKI LEE | President | — | 2026-02-25 00:00:00 | D |
| 2 | 9896 | 44675.0 | — | Sale at price 4.51 per share. | MORRISON JODIE POPE | Chief Executive Officer | — | 2026-02-25 00:00:00 | D |
| 3 | 9072 | 31395.0 | — | Sale at price 3.46 per share. | KALOWSKI LEE | President | — | 2025-12-02 00:00:00 | D |
| 4 | 22506 | 77871.0 | — | Sale at price 3.46 per share. | MORRISON JODIE POPE | Chief Executive Officer | — | 2025-12-02 00:00:00 | D |
| 5 | 2990 | 5385.0 | — | Sale at price 1.80 per share. | VIOLETTE SHELIA M | Officer | — | 2025-08-26 00:00:00 | D |
| 6 | 4240 | 7636.0 | — | Sale at price 1.80 per share. | KALOWSKI LEE | President | — | 2025-08-26 00:00:00 | D |
| 7 | 10494 | 18900.0 | — | Sale at price 1.80 per share. | MORRISON JODIE POPE | Chief Executive Officer | — | 2025-08-26 00:00:00 | D |
| 8 | 53250 | — | — | Stock Award(Grant) at price 0.00 per share. | KALOWSKI LEE | Chief Executive Officer | — | 2025-02-24 00:00:00 | D |
| 9 | 132000 | — | — | Stock Award(Grant) at price 0.00 per share. | MORRISON JODIE POPE | Chief Executive Officer | — | 2025-02-24 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -1.30M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -59.69M | -41.56M | -36.45M | -36.65M |
| TotalUnusualItems | 15.19M | -6.19M | -2.40M | |
| TotalUnusualItemsExcludingGoodwill | 15.19M | -6.19M | -2.40M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -47.73M | -53.74M | -42.81M | -37.56M |
| ReconciledDepreciation | 487.00K | 499.00K | 370.00K | 47.00K |
| EBITDA | -44.50M | -47.76M | -38.85M | -36.65M |
| EBIT | -44.99M | -48.26M | -39.23M | -36.69M |
| NetInterestIncome | 2.80M | |||
| InterestExpense | 1.10M | |||
| InterestIncome | 3.90M | |||
| NormalizedIncome | -62.92M | -48.85M | -40.41M | -37.56M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -47.73M | -53.74M | -42.81M | -37.56M |
| TotalExpenses | 66.10M | 41.60M | 45.88M | 36.69M |
| TotalOperatingIncomeAsReported | -66.10M | -48.26M | -39.23M | -36.69M |
| DilutedAverageShares | 9.66M | 11.93M | 11.93M | 11.93M |
| BasicAverageShares | 9.32M | 11.93M | 11.93M | 11.93M |
| DilutedEPS | -6.58 | -4.51 | -3.59 | -3.15 |
| BasicEPS | -5.12 | -4.51 | -3.59 | -3.15 |
| DilutedNIAvailtoComStockholders | -63.53M | -53.74M | -42.81M | -37.56M |
| NetIncomeCommonStockholders | -47.73M | -53.74M | -42.81M | -37.56M |
| NetIncome | -47.73M | -53.74M | -42.81M | -37.56M |
| NetIncomeIncludingNoncontrollingInterests | -47.73M | -53.74M | -42.81M | -37.56M |
| NetIncomeContinuousOperations | -47.73M | -53.74M | -42.81M | -37.56M |
| EarningsFromEquityInterestNetOfTax | -1.62M | 0.00 | ||
| TaxProvision | 21.00K | 318.00K | 62.00K | 547.00K |
| PretaxIncome | -46.09M | -53.42M | -42.75M | -37.02M |
| OtherIncomeExpense | 17.21M | -5.17M | -3.52M | -324.00K |
| OtherNonOperatingIncomeExpenses | 2.02M | 1.02M | -1.12M | -324.00K |
| SpecialIncomeCharges | -700.00K | |||
| WriteOff | 700.00K | |||
| GainOnSaleOfSecurity | 15.89M | -6.19M | -2.40M | |
| NetNonOperatingInterestIncomeExpense | 2.80M | |||
| InterestExpenseNonOperating | 1.10M | |||
| InterestIncomeNonOperating | 3.90M | |||
| OperatingIncome | -66.10M | -48.26M | -39.23M | -36.69M |
| OperatingExpense | 66.10M | 41.60M | 45.88M | 36.69M |
| ResearchAndDevelopment | 48.14M | 31.73M | 35.81M | 29.93M |
| SellingGeneralAndAdministration | 17.96M | 9.88M | 10.06M | 6.76M |
| GeneralAndAdministrativeExpense | 17.96M | 9.88M | 10.06M | 6.76M |
| OtherGandA | 17.96M | 9.88M | 10.06M | 6.76M |
| TotalRevenue | 0.00 | -6.65M | 6.65M | 0.00 |
| OperatingRevenue | 0.00 | -6.65M | 6.65M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 12.20M | 11.93M | 11.93M | 11.93M |
| ShareIssued | 12.20M | 11.93M | 11.93M | 11.93M |
| NetDebt | 18.44M | |||
| TotalDebt | 18.90M | 50.84M | 44.73M | 4.97M |
| TangibleBookValue | 5.67M | -182.92M | -130.71M | -89.21M |
| InvestedCapital | 18.33M | -138.87M | -93.24M | -84.24M |
| WorkingCapital | 65.41M | 14.61M | -11.01M | 26.78M |
| NetTangibleAssets | 5.67M | -182.92M | -130.71M | -89.21M |
| CapitalLeaseObligations | 6.25M | 6.79M | 7.26M | 0.00 |
| CommonStockEquity | 5.67M | -182.92M | -130.71M | -89.21M |
| PreferredStockEquity | 111.44M | 111.44M | ||
| TotalCapitalization | 15.23M | -139.75M | -125.64M | -84.24M |
| TotalEquityGrossMinorityInterest | 5.67M | -182.92M | -130.71M | -89.21M |
| StockholdersEquity | 5.67M | -182.92M | -130.71M | -89.21M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 0.00 | ||
| RetainedEarnings | -234.81M | -187.08M | -133.34M | -90.53M |
| AdditionalPaidInCapital | 240.49M | 4.16M | 2.62M | 1.32M |
| CapitalStock | 2.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 2.00K | 1.00K | 1.00K | 1.00K |
| PreferredStock | 111.44M | 111.44M | ||
| TotalLiabilitiesNetMinorityInterest | 86.66M | 229.98M | 192.49M | 124.36M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 70.19M | 215.87M | 134.62M | 117.14M |
| OtherNonCurrentLiabilities | 55.00M | 55.00M | 728.00K | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 111.44M | 111.44M | 111.44M |
| NonCurrentDeferredLiabilities | 11.32M | 0.00 | ||
| NonCurrentDeferredRevenue | 11.32M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 15.19M | 49.42M | 11.86M | 4.97M |
| LongTermCapitalLeaseObligation | 5.64M | 6.25M | 6.79M | 0.00 |
| LongTermDebt | 9.56M | 43.18M | 5.07M | 4.97M |
| CurrentLiabilities | 16.46M | 14.11M | 57.87M | 7.22M |
| OtherCurrentLiabilities | 2.90M | |||
| CurrentDeferredLiabilities | 14.53M | 0.00 | ||
| CurrentDeferredRevenue | 14.53M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 3.71M | 1.42M | 32.87M | |
| CurrentCapitalLeaseObligation | 612.00K | 538.00K | 471.00K | 0.00 |
| CurrentDebt | 3.10M | 878.00K | 32.40M | |
| OtherCurrentBorrowings | 3.10M | 878.00K | 32.40M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.78M | 3.00M | 2.79M | 1.49M |
| PayablesAndAccruedExpenses | 7.07M | 9.69M | 7.67M | 5.73M |
| CurrentAccruedExpenses | 4.08M | 5.91M | 5.67M | 3.05M |
| InterestPayable | 376.00K | 0.00 | ||
| Payables | 2.99M | 3.78M | 2.00M | 2.68M |
| TotalTaxPayable | 0.00 | 316.00K | 570.00K | 0.00 |
| AccountsPayable | 2.99M | 3.47M | 1.44M | 2.68M |
| TotalAssets | 92.33M | 47.06M | 61.77M | 35.15M |
| TotalNonCurrentAssets | 10.46M | 18.34M | 14.92M | 1.15M |
| OtherNonCurrentAssets | 647.00K | 5.67M | 5.75M | 950.00K |
| NonCurrentPrepaidAssets | 116.00K | 676.00K | ||
| NonCurrentDeferredAssets | 0.00 | 3.91M | ||
| InvestmentsAndAdvances | 2.60M | 0.00 | ||
| LongTermEquityInvestment | 2.60M | 0.00 | ||
| NetPPE | 7.09M | 8.08M | 9.17M | 203.00K |
| AccumulatedDepreciation | -1.45M | -966.00K | -467.00K | -102.00K |
| GrossPPE | 8.54M | 9.05M | 9.63M | 305.00K |
| Leases | 1.00M | 940.00K | 935.00K | 0.00 |
| OtherProperties | 7.10M | 7.68M | 8.27M | 220.00K |
| MachineryFurnitureEquipment | 440.00K | 426.00K | 426.00K | 85.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 81.88M | 28.72M | 46.85M | 34.00M |
| OtherCurrentAssets | 396.00K | 83.00K | 146.00K | 73.00K |
| PrepaidAssets | 2.96M | 2.26M | 1.75M | 769.00K |
| Receivables | 555.00K | 755.00K | 1.06M | 909.00K |
| OtherReceivables | 116.00K | 282.00K | ||
| TaxesReceivable | 555.00K | 755.00K | 948.00K | 627.00K |
| CashCashEquivalentsAndShortTermInvestments | 77.97M | 25.62M | 43.89M | 32.25M |
| CashAndCashEquivalents | 77.97M | 25.62M | 43.89M | 32.25M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -67.79M | -18.68M | -13.44M | -33.14M |
| RepaymentOfDebt | 0.00 | -5.20M | ||
| IssuanceOfDebt | 7.00M | 5.50M | 30.00M | 0.00 |
| IssuanceOfCapitalStock | 42.00M | 0.00 | 0.00 | 19.99M |
| CapitalExpenditure | -75.00K | -5.00K | -2.48M | -157.00K |
| InterestPaidSupplementalData | 856.00K | 422.00K | ||
| EndCashPosition | 78.61M | 31.26M | 49.54M | 32.98M |
| BeginningCashPosition | 31.26M | 49.54M | 32.89M | 45.92M |
| ChangesInCash | 47.35M | -18.28M | 16.65M | -12.94M |
| FinancingCashFlow | 95.14M | 406.00K | 30.07M | 20.11M |
| CashFlowFromContinuingFinancingActivities | 95.14M | 406.00K | 30.07M | 20.11M |
| NetOtherFinancingCharges | 44.44M | |||
| ProceedsFromStockOptionExercised | 1.69M | 106.00K | 69.00K | 115.00K |
| NetPreferredStockIssuance | 0.00 | 19.99M | ||
| PreferredStockIssuance | 0.00 | 19.99M | ||
| NetCommonStockIssuance | 42.00M | 0.00 | 69.00K | 115.00K |
| CommonStockIssuance | 42.00M | 0.00 | 69.00K | 115.00K |
| NetIssuancePaymentsOfDebt | 7.00M | 300.00K | 30.00M | 0.00 |
| NetShortTermDebtIssuance | 30.00M | 0.00 | ||
| ShortTermDebtIssuance | 30.00M | 0.00 | ||
| NetLongTermDebtIssuance | 7.00M | 300.00K | ||
| LongTermDebtPayments | 0.00 | -5.20M | ||
| LongTermDebtIssuance | 7.00M | 5.50M | ||
| InvestingCashFlow | 19.93M | -5.00K | -2.47M | -157.00K |
| CashFlowFromContinuingInvestingActivities | 19.93M | -5.00K | -2.47M | -157.00K |
| NetInvestmentPurchaseAndSale | 20.00M | 0.00 | ||
| SaleOfInvestment | 20.00M | 0.00 | ||
| NetPPEPurchaseAndSale | -75.00K | -5.00K | -2.47M | -157.00K |
| SaleOfPPE | 19.00K | 0.00 | ||
| PurchaseOfPPE | -75.00K | -5.00K | -2.48M | -157.00K |
| OperatingCashFlow | -67.72M | -18.68M | -10.96M | -32.98M |
| CashFlowFromContinuingOperatingActivities | -67.72M | -18.68M | -10.96M | -32.98M |
| ChangeInWorkingCapital | -9.64M | 26.32M | 26.94M | 3.68M |
| ChangeInOtherWorkingCapital | -25.85M | 25.85M | ||
| ChangeInOtherCurrentLiabilities | -1.54M | 54.53M | -409.00K | 0.00 |
| ChangeInOtherCurrentAssets | 386.00K | -4.50M | 195.00K | -244.00K |
| ChangeInPayablesAndAccruedExpense | -8.76M | 2.23M | 2.52M | 4.02M |
| ChangeInAccruedExpense | -7.71M | 199.00K | 3.76M | 2.92M |
| ChangeInPayable | -1.04M | 2.03M | -1.24M | 1.10M |
| ChangeInAccountPayable | -1.04M | 2.03M | -1.24M | 1.10M |
| ChangeInPrepaidAssets | 276.00K | -94.00K | -1.21M | -96.00K |
| OtherNonCashItems | -1.41M | 631.00K | 876.00K | 102.00K |
| StockBasedCompensation | 4.39M | 1.43M | 1.24M | 753.00K |
| UnrealizedGainLossOnInvestmentSecurities | -15.89M | 6.19M | 2.40M | 0.00 |
| AssetImpairmentCharge | 675.00K | 0.00 | ||
| AmortizationOfSecurities | -221.00K | 0.00 | ||
| DepreciationAmortizationDepletion | 487.00K | 499.00K | 370.00K | 47.00K |
| DepreciationAndAmortization | 487.00K | 499.00K | 370.00K | 47.00K |
| Depreciation | 487.00K | 499.00K | 370.00K | 47.00K |
| OperatingGainsLosses | 1.62M | 23.00K | ||
| EarningsLossesFromEquityInvestments | 1.62M | 0.00 | ||
| GainLossOnSaleOfPPE | 23.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -47.73M | -53.74M | -42.81M | -37.56M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for QTTB
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|